260 References Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008 Feb;134(2):577594. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011 May 01;140(6):1785-1794. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn’s disease--based on results from a regional patient group from the county of Copenhagen. Gut 1985 February 01;26(2):146-150. Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 2017 February 01;152(2):361.e5. Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008 November 01;6(11):1218-1224. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008 January 01;14(1):40-46. Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut 2013 December 01;62(12):1806-1816. Boschetti G, Garnero P, Moussata D, Cuerq C, Preaudat C, Duclaux-Loras R, et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn’s disease. Inflamm Bowel Dis 2015 February 01;21(2):331-336. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008 January 01;103(1):162169. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000 October 01;47(4):506-513. Foell D,Wittkowski H, Roth J. Monitoring disease activity by stool analyses: fromoccult blood tomolecular markers of intestinal inflammation and damage. Gut 2009 June 01;58(6):859-868. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol 2015 January 01;8(1):23-36. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012 January 10;12:5. Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology 2015 October 01;149(5):1285.e2. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 2009 August 01;58(8):1152-1167. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 July 01;109(1):129-135. Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev 2017 April 01;16(4):416-426. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014 May 01;14(5):329-342. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012 November 03;380(9853):1590-1605. O’Connor W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009 June 01;10(6):603-609. Chapter 7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
RkJQdWJsaXNoZXIy MjY0ODMw